Search MalaCards:
MCID: MLT019

Multiple Myeloma malady
27 drugs, 755 genes, 24 tissues, 816 related diseases, 29 phenotypes, 1520 articles, clinical trials.

Summaries for Multiple Myeloma

about this section
Sources:
6Disease Ontology, 30NIH Rare Diseases, 23MedlinePlus, 44Wikipedia, 22MalaCards
See all sources

Export this MalaCard
MedlinePlus: Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. these cells are part of your immune system, which helps protect the body from germs and other harmful substances. in time, myeloma cells collect in the bone marrow and in the solid parts of bone. no one knows the exact causes of multiple myeloma, but it is more common in older people and african-americans. early symptoms may include bone pain, often in the back or ribs broken bones weakness or fatigue weight loss repeated infections myeloma is hard to cure. treatment may help control symptoms and complications. options include chemotherapy, stem cell transplantation and radiation. nih: national cancer institute23

MalaCards: Multiple Myeloma, also known as plasma cell myeloma, is related to myeloma and leukemia. An important gene associated with Multiple Myeloma is IRF4 (interferon regulatory factor 4), and among its related pathways are STAT3 Pathway and Jak-STAT signaling pathway. The drugs zoledronic and carmustine and the compounds calcium and nitric oxide have been mentioned in the context of this disorder. Affiliated tissues include the plasma cells in bone marrow, bone marrow and whole blood, and related mouse phenotypes are cellular and homeostasis/metabolism.

Disease Ontology: A myeloma that is located in the plasma cells in bone marrow.6

NIH Rare Diseases: Multiple myeloma is a cancer of the plasma cells in the bone marrow. Plasma cells help the body fight infection by producing proteins called antibodies. In multiple myeloma, plasma cells grow out of control in the bone marrow and form tumors in the areas of solid bone. The growth of these bone tumors makes it harder for the bone marrow to make healthy blood cells and platelets. This disease may also harm other tissues and organs, such as the kidneys. Multiple myeloma mainly affects older adults. Although the exact cause is unknown, there are several known risk factors that can increase a person's chance of getting this disease.30

Wikipedia: Multiple myeloma (from Greek myelo-, bone marrow), also known as plasma cell myeloma or Kahler\'s...44 more...

Aliases & Descriptions for Multiple Myeloma

about this section
Sources:
6Disease Ontology, 7diseasecard, 30NIH Rare Diseases, 8DISEASES, 33OMIM, 23MedlinePlus, 43UMLS, 32Novoseek , 40SNOMED-CT, 19ICD9CM, 27NCIt, 24MeSH
See all sources

Aliases & Descriptions:

multiple myeloma 6 7 30 8 33 23 43
plasma cell myeloma 30 32
plasma cell dyscrasia 30
myeloma - multiple 30
kahler disease 30
myelomatosis 30

External Ids:

ICD9CM19 203.0
NCIt27 C3242
SNOMED-CT40 154585004, 55921005, 94705007 109989006, more

Related Diseases for Multiple Myeloma

about this section
Sources:
13GeneCards, 14GeneDecks
See all sources

Diseases related to multiple myeloma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 813)
idRelated DiseaseScoreTop Affiliating Genes
1myeloma134.9PIK3CA, PIAS3, PIK3R2, PIK3R1, PIK3CG, LRP1
2leukemia102.3PIK3CA, PIK3R2, PIK3R1, PIK3CG, LRP1, NCAM1
3carcinoma101.5PIK3CA, PIAS3, PIK3R2, PIK3R1, PIK3CG, LRP1
4prostatitis83.7PIK3CA, PIAS3, PIK3R2, PIK3R1, PIK3CG, LRP1
5lymphocytic leukemia70.4PIK3CA, PIK3CG, NCAM1, RECK, REL, RELA
6myeloid leukemia66.8PIK3CA, PIK3R2, PIK3R1, PIK3CG, NCAM1, NCOR2
7thyroiditis60.5PIK3CA, PIK3R1, PIK3CG, LRP1, NCAM1, NCOR2
8cervicitis58.5PIK3CA, PIK3CG, NCR1, RECK, RELA, KIT
9breast carcinoma58.2PIK3CA, PIK3R1, PIK3CG, LRP1, RECK, KIT
10acute myeloid leukemia58.2PIK3CA, PIK3R2, PIK3R1, PIK3CG, NCAM1, NCOR2
11hypoxia55.5PIK3CA, PIK3R1, PIK3CG, LRP1, RECK, RELA
12acute leukemia54.6PIK3CA, NCAM1, NCOR2, KIT, KITLG, VWF
13non-hodgkin lymphoma52.2NCOR2, KITLG, NAT1, NAT2, MYC, BMI1
14diffuse large b-cell lymphoma52.1PIK3CA, PIK3CG, NCAM1, REL, RELA, KIT
15anemia51.7NCAM1, RELA, KIT, KITLG, VWF, PCNA
16adenoma49.1PIK3CA, NCAM1, NCOR2, RECK, CNTF, KIT
17chronic lymphocytic leukemia47.4REL, BIRC2, BIRC3, BIRC5, PAX5, BCL10
18squamous cell carcinoma47.4PIK3CA, RECK, RELA, VTN, PCNA, RB1
19b-cell lymphomas47.0REL, RB1, MYC, BMI1, BIK, BIRC2
20hodgkin's lymphoma46.2PIK3R1, PIK3CG, REL, SELP, BMI1, RAG2
21mantle cell lymphoma45.7PIK3CA, PIK3CG, KIT, SFRP1, RB1, VEGFA
22t-cell leukemia43.8PIK3CG, REL, RELA, MYC, RAG2, RAG1
23retinoblastoma43.7PIK3CA, PIK3R1, PIK3CG, NCAM1, RECK, KIT
24hematopoiesis43.6PIK3R1, PIK3CG, KIT, KITLG, PCNA, RB1
25melanoma43.0PIK3CA, PIK3R2, PIK3R1, PIK3CG, LRP1, NCAM1
26nephropathy42.5LRP1, RELA, KITLG, VWF, VTN, PCNA
27pancreatitis42.1PIK3CA, PIK3R2, PIK3R1, PIK3CG, LRP1, NCAM1
28plasmacytoma41.9VEGFA, MYC, LIF, PAX5, BCL2, BCL2L1
29arthritis41.8PIK3CG, LRP1, PDCD5, RECK, REL, RELA
30burkitt's lymphoma41.8MYC, BMI1, BMP6, RAG1, BIRC2, BIRC3
31pneumonia41.7RELA, VTN, RBP4, SERPINC1, SETD2, NAGLU
32neuronitis41.5PIK3CA, PIK3R2, PIK3R1, PIK3CG, LRP1, NCAM1
33leukemia/lymphoma40.8PIK3CA, PIK3CG, REL, KITLG, RB1, VEGFA
34immunodeficiency40.6MYD88, BMP6, PARP1, CIITA, CISH, ZAP70
35measles40.4PIK3CA, PIK3R2, PIK3R1, PIK3CG, RECK, RELA
36hepatocellular carcinoma40.3PIK3CA, PIK3R1, PIK3CG, NCAM1, RECK, RELA
37macroglobulinemia40.2PIK3CG, KITLG, VEGFA, BLNK, BIRC3, PAX5
38adenocarcinoma40.0PIK3CA, PIK3R1, PIK3CG, LRP1, NCAM1, PDCD5
39monoclonal gammopathy of undetermined significance40.0NCAM1, VWF, VCAM1, MYOM2, B2M, CD79A
40myelodysplastic syndrome40.0KIT, KITLG, BMI1, RAN, BIRC5, MVP
41rheumatoid arthritis39.9PIK3CG, LRP1, PDCD5, RECK, REL, RELA
42hypercalcemia39.6BMP6, LIF, BGLAP, SCT, B2M, CD36
43osteoporosis39.2SFRP1, RBP4, SERPINC1, VEGFA, BMP2, BMP4
44liver cancer38.9PIK3CG, SFRP2, RB1, SETD2, NAT1, NAT2
45severe combined immunodeficiency38.9KITLG, PCNA, SELP, VHL, VEGFA, MYC
46combined immunodeficiency38.1KITLG, PCNA, SELP, VHL, VEGFA, MYC
47waldenstrom macroglobulinemia38.1PIK3CG, KITLG, VEGFA, BLNK, BIRC3, PAX5
48lateral sclerosis37.6CNTF, SETD2, VEGFA, RAC1, LIF, BID
49ovarian cancer37.5PIK3CA, PIK3R1, PIK3CG, LRP1, NCAM1, NCOR2
50amyotrophic lateral sclerosis37.5CNTF, SETD2, VEGFA, RAC1, LIF, BID

Graphical network of the top 20 diseases related to multiple myeloma:



Graphical network of diseases related to multiple myeloma

Clinical Features for Multiple Myeloma

about this section

Drugs & Therapeutics for Multiple Myeloma

about this section
Sources:
4CenterWatch, 29NIH Clinical Center, 5ClinicalTrials, 21LifeMap Discovery™, 43UMLS, 28NDF-RT
See all sources

Approved drugs:

Search CenterWatch for multiple myeloma

Drug clinical trials:

Search ClinicalTrials for multiple myeloma

Search NIH Clinical Center for multiple myeloma

Search CenterWatch for multiple myeloma

Inferred drug relations via UMLS/NDF-RT:

43 28 aldesleukin, bortezomib, carmustine, cisplatin, cisplatin pwdr [va product], cyclophosphamide, doxorubicin hydrochloride, interferon, interferon alfa 2-b, interferon alfa-2a, interferon alfa-2a,recombinant, interferon alfa-2b, interferon alfa-2b,recombinant, interferon alfa-3n,human leukocyte derived, interferon alfacon-1, interferon beta-1a,recombinant, interferon beta-1b,recombinant, interferon gamma-1b, melphalan, melphalan hydrochloride, peginterferon alfa-2a, peginterferon alfa-2b, procarbazine, procarbazine hydrochloride, thalidomide, zoledronic, zoledronic acid

Cell-based therapeutics:


LifeMap Discovery
The database of embryonic development, stem cell research and regenerative medicine
Stem-Cell-Based therapeutic approaches for multiple myeloma:
Blood stem cell transplantation in Hodgkin's/non-Hodgkin's lymphoma, multiple myeloma or chronic lymphocytic leukemia patients
Donor peripheral blood stem cell transplantation in patients with hematologic malignancies
Embryonic/Adult Cultured Cells Related to multiple myeloma:
Peripheral blood/mobilized hematopoietic stem cells, PMIDs: 19015394, 17916744, 18794548
Peripheral blood/mobilized hematopoietic stem cells, PMIDs: 12171484, 19925877, 18489989

Genetic Tests for Multiple Myeloma

about this section

Anatomical Context for Multiple Myeloma

about this section
Sources:
21LifeMap Discovery™, 11FMA, 22MalaCards
See all sources

MalaCards organs/tissues related to multiple myeloma:

22
Bone marrow, Whole blood, Lymph node, Brain, Heart, Skeletal muscle, Kidney, Liver, Lung, Thyroid, Breast, Skin, Prostate, Testis, Myeloid, Monocytes, Nk cells, T cells, B cells, Endothelial, Pituitary

FMA organs/tissues related to multiple myeloma:

11
The plasma cells in bone marrow

LifeMap Discovery
The database of embryonic development, stem cell research and regenerative medicine

Embryonic and adult cells/anatomical compartments related to multiple myeloma:
id Organ / Tissue -> Anatomical Compartment -> Cell Relevance
1 Bone -> Bone Marrow -> Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood -> Peripheral Blood -> Mature B Cells Potential therapeutic candidate, affected by disease

Phenotypes for genes affiliated with Multiple Myeloma

about this section
Sources:
25MGI
See all sources

MGI Mouse Phenotypes related to multiple myeloma:

25 (show all 29)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1cellular phenotypeMP:000538439.0PIK3CA, PIK3R1, PIK3CG, NCAM1, NCOR2, REL
2homeostasis/metabolism phenotypeMP:000537635.5PIK3CA, PIK3R2, PIK3R1, PIK3CG, LRP1, NCOR2
3mortality/agingMP:001076835.1PIK3CA, LRP1, NCAM1, NCOR2, NCR1, RECK
4hematopoietic system phenotypeMP:000539731.9NCR1, CNTF, KIT, SFRP1, PCNA, BST2
5growth/size phenotypeMP:000537831.1PIK3CA, PIK3R1, PIK3CG, LRP1, NCOR2, RECK
6immune system phenotypeMP:000538727.3LRP1, REL, RELB, CNTF, KIT, VWF
7cardiovascular system phenotypeMP:000538526.6PIK3CA, PIK3R2, PIK3R1, PIK3CG, LRP1, NCOR2
8nervous system phenotypeMP:000363125.2LRP1, RECK, REL, RELA, CNTF, KIT
9normal phenotypeMP:000287323.8PIK3R1, LRP1, NCR1, RELA, VTN, SFRP2
10behavior/neurological phenotypeMP:000538623.6PIK3CA, LRP1, NCAM1, NCOR2, RELB, CNTF
11integument phenotypeMP:001077122.0PIK3CG, RECK, REL, RELA, RELB, KIT
12skeleton phenotypeMP:000539019.9PIK3CG, LRP1, RECK, REL, RELA, KIT
13embryogenesis phenotypeMP:000538019.6PIK3CA, RECK, REL, KIT, KIF11, SFRP1
14tumorigenesisMP:000200618.9PIK3CA, PIK3R2, PIK3R1, KIT, KITLG, RB1
15renal/urinary system phenotypeMP:000536718.6KIT, SFRP4, SELP, NAGLU, BRAF, VHL
16digestive/alimentary phenotypeMP:000538118.2NCOR2, REL, RELB, KIT, KITLG, VWF
17vision/eye phenotypeMP:000539118.2PIK3CA, NCAM1, RELA, KIT, KITLG, RB1
18muscle phenotypeMP:000536917.5PIK3CA, PIK3R2, PIK3R1, PIK3CG, LRP1, RELA
19reproductive system phenotypeMP:000538917.1PIK3CA, KIF11, SFRP2, SFRP4, SFRP5, RBP4
20craniofacial phenotypeMP:000538216.9NCOR2, KIT, KITLG, NAGLU, BMI1, BMP4
21no phenotypic analysisMP:000301216.9PIK3R1, SFRP1, SFRP2, PCNA, RB1, SEMA3A
22limbs/digits/tail phenotypeMP:000537116.8RECK, RELA, RELB, KIT, KITLG, SFRP1
23liver/biliary system phenotypeMP:000537016.0NCOR2, RECK, REL, RELB, KIT, SERPINC1
24respiratory system phenotypeMP:000538815.4REL, RELB, SFRP4, NBEA, SELP, SEMA3A
25hearing/vestibular/ear phenotypeMP:000537715.2KIT, KITLG, RB1, NAGLU, MYC, MYD88
26endocrine/exocrine gland phenotypeMP:000537914.3RELB, SFRP2, SFRP5, RAD23B, BIK, BDKRB2
27adipose tissue phenotypeMP:000537513.3PIK3CA, PIK3R1, LRP1, NCOR2, SFRP1, RB1
28pigmentation phenotypeMP:000118612.7KIT, KITLG, RB1, SERPINC1, NAGLU, BRAF
29other phenotypeMP:000539511.7RECK, RELB, KDR, JAK2, CDKN2A, CD40LG

Publications for genes affiliated with Multiple Myeloma

about this section
Sources:
35PubMed
See all sources

Articles related to multiple myeloma:

(show top 50)    (show all 1520)
idTitleAuthorsYearAffiliating Genes
1Knockdown of c-Met inhibits cell proliferation and in vasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro. (21468575)Que W.... Chen J.2011MET
2Surface molecule CD229 as a novel target for the diag nosis and treatment of multiple myeloma. (21606160)Atanackovic D.... KrAPger N.2011LY9
3Polymorphisms of nuclear factor-I_B family genes are a ssociated with development of multiple myeloma and treatment outcome in patient s receiving bortezomib-based regimens. (21228035)Du J.... Hou J.2011NFKBIA, TRAF3, NFKB2
4BAFF-R gene induced by IFN-I^ in multiple myeloma cell s is related to NF-I_B signals. (21744373)Shen X.... Ju S.2011TNFRSF13C
5The G-Allele of the PSMA6-8C>G polymorphism is ass ociated with poor outcome in multiple myeloma independently of circulating prot easome serum levels. (20408869)Bachmann H.S.... NA1ckel H.2010PSMA6
6Inhibition of proliferation and induction of apoptosi s in multiple myeloma cell lines by CD137 ligand signaling. (20520765)Gullo C.... Schwarz H.2010TNFSF9
7Expression of WT1 gene in multiple myeloma patients a t diagnosis: is WT1 gene expression a useful marker in multiple myeloma? (20132661)Saatci C.... Ozkul Y.2010WT1
8Analysis of NOTCH1 extracellular juxtamembrane expansion mutations in acute leukemias and multiple myelomas. (19239437)Kim Y.R.... Lee S.H.2009NOTCH1
9Enzyme levels and G-463A polymorphism of myeloperoxid ase in chronic lymphocytic leukemia and multiple myeloma. (19814685)Saygili E.I.... Pehlivan S.2009MPO
10Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count. (18996035)Perosa F.... Dammacco F.2009CD40LG
11Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. (19147543)Kunnumakkara A.B.... Aggarwal B.B.2009CCND1, PTPN6, STAT3
12Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. (19167685)Stiff P.... Calandra G.2009CSF3
13Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma. (19736056)Gold L.S.... Baris D.2009CYP1B1, NQO1, CYP2C9
14MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells. (18575761)Kawano T.... Kufe D.2008MUC1
15Thromboembolic events with lenalidomide-based therapy for multiple myeloma. (18278812)Menon S.P.... Palumbo A.2008EPO
16Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. (18594024)Sarasquete M.E.... San Miguel J.F.2008CYP2C8
17Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systema tic comparison. (17608711)Prince H.M.... Hertel J.2007B2M
18Control of apoptosis in human multiple myeloma by ins ulin-like growth factor I (IGF-I). (17419944)Jernberg-Wiklund H.... Nilsson K.2007IGF1R, IGF1
19Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma. (17036375)Intini D.... Neri A.2007NRAS
20CD28-mediated regulation of multiple myeloma cell proliferation and survival. (17311991)Bahlis N.J.... Lee K.P.2007PIK3CG, CD28, CD80
21Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma. (17926179)Abazis-Stamboulieh D.... Tsezou A.2007IL1B, IL1A, IL1RN
22The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. (17418411)Carrasco D.R.... DePinho R.A.2007XBP1
23The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease. (16831934)Brunetti G.... Grano M.2006TNFRSF11B, TNFSF10
24Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. (15586381)Kremer M.... Fend F.2005BCL2, CCND1, BCL2L1
25Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma. (15725479)Kikuchi Y.... Fukushima N.2005CD47
26Cytogenetic manifestations of multiple myeloma heterogeneity. (15495197)Pantou D.... Bardi G.2005CCND1
27ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. (16044163)Suzuki A.... Esumi H.2005IGF1, NUAK1
28Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines. (15077927)Alexandrakis M.G.... Kyriakou D.S.2004IL1B, LEP, B2M
29Advances in biology and therapy of multiple myeloma. (14633785)Barille-Nion S.... Tricot G.2003FGFR3, CCND1, CCND3
30Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. (12631257)Terpos E.... Rahemtulla A.2003IL6, B2M, CRP
31An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth. (12569357)Crowder C.... Rudikoff S.2003HRAS
32Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin's lymphoma or multiple myeloma. (12648076)Lincz L.F.... Enno A.2003MTR, MTHFR
33The induction of apoptosis by a combined 1,25(OH)2D3 analog, EB1089 and TGF-beta1 in NCI-H929 multiple myeloma cells. (11836565)Park W.H.... Lee Y.Y.2002CDK4, CDK2, TGFB1
34Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma. (12482123)JurisiA8 V.... ColoviA8 M.2002TNF
35Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. (12242656)Pene F.... Bouscary D.2002CCND1, IGF1, RPS6KB1
36Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. (12367766)Alexandrakis M.G.... Margioris A.N.2002B2M, CD36, BGLAP
37Antiangiogenic therapy in multiple myeloma. (11815718)Tosi P.... Tura S.2001KDR
38Influence of thalidomide on Bcl2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients. (11985351)DmoszyA8ska A.... Hus M.2001BCL2, TNF, IL6
39Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. (11562486)Pearse R.N.... Choi Y.2001TNFRSF11B, TNFSF11
40A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete resp onse rates in advanced multiple myeloma. (10886221)Moreau P.... Bataille R.2000IL6
41Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma) (10916207)Spicka I.... Klener P.2000IL6, SLPI
42Advances in the biology of multiple myeloma: therapeu tic applications. (10528890)Anderson K.1999TGIF1
43Metastatic cutaneous plasmacytoma: a case report associated with IgA lambda multiple myeloma and a review of the literature of metastatic cutaneous plasmacytomas associated with multiple myeloma and primary cutaneous plasmacytomas. (10535253)Kato N.... Aikawa K.1999CD79A
44Circadian rhythm of serum erythropoietin in multiple myeloma. (8813096)Pasqualetti P.... Casale R.1996EPO
45Recombinant human erythropoietin in transfusion-depen dent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a random ized multicenter study. The European Study Group of Erythropoietin (Epoetin Bet a) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. (8639883)Osterborg A.... Peest D.1996EPO
46The oncoprotein phenotype of plasma cells from patients with multiple myeloma. (7696921)Brown R.D.... Joshua D.1994MYC, BCL2
47Randomised trial of intravenous immunoglobulin as pro phylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. (7909099)Chapel H.M.... Prentice A.G.1994ALB
48Prognostic effect of beta 2-microglobulin in multiple myeloma (1447935)Ortega F.... Sanz M.1992B2M
49Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. (1482651)Beguin Y.... Fillet G.1992TFRC, EPO
50Colony stimulating activity in the serum of patients with multiple myeloma is enhanced by interleukin 3: a possible role for interle ukin 3 after high dose melphalan and autologous bone marrow transplantation for multiple myeloma. (2201402)Millar B.C.... McElwain T.J.1990IL3

Expression for genes affiliated with Multiple Myeloma

about this section
Sources:
1BioGPS
See all sources
Expression patterns in normal tissues for genes affiliated with Multiple Myeloma

Pathways for genes affiliated with Multiple Myeloma

about this section
Sources:
36QIAGEN, 20KEGG, 10EMD Millipore, 41Thomson Reuters, 37R&D Systems, 34PharmGKB
See all sources

Pathways related to multiple myeloma according to GeneDecks:

(show top 50)    (show all 414)
idPathwayScoreTop Affiliating Genes
1STAT3 Pathway3619.0BRAF, MYC, BMP2, BMP4, BMP6, RAF1
2Jak-STAT signaling pathway2015.3PIK3CA, PIAS3, PIK3R2, PIK3R1, PIK3CG, CNTF
3Pathways in cancer2014.8PIK3CA, PIAS3, PIK3R2, PIK3R1, PIK3CG, RELA
4NF-KappaB (p50-p65) Pathway3614.2PIK3R2, PIK3R1, RELA, KITLG, SEMA3A, MYD88
5Apoptosis and survival Anti-apoptotic TNFs/NF-kB/IAP pathway1013.7REL, RELA, RELB, BIRC2, BIRC3, BIRC5
6Signal transduction_AKT signaling4113.6PIK3CA, PIK3R2, PIK3R1, REL, RELA, RELB
7Toll-like receptor signaling pathway2013.5PIK3CA, PIK3R2, PIK3R1, PIK3CG, RELA, MYD88
8PPAR Pathway3613.5PIK3R1, KIT, KITLG, SEMA3A, BMP2, BMP4
9Influenza A2013.4PIK3CA, PIK3R2, PIK3R1, PIK3CG, RELA, MYD88
10NFAT Signaling and Lymphocyte Interactions3613.4BMP2, BMP4, BMP6, BCL2, BAX, CD3D
11Apoptosis and survival APRIL and BAFF signaling1013.2RELA, RELB, BCL2, BCL2L1, CHUK, IL10
12TNF Signaling3612.8BID, BIRC2, BIRC3, CHUK, ATF6, JUN
13Immune response IL-9 signaling pathway1012.7PIK3R2, RELA, RAF1, CISH, JAK1, IRS1
14eIF2 Pathway3612.7PIK3R2, PIK3R1, KIT, KITLG, SEMA3A, BRAF
15Development PDGF signaling via STATs and NF-kB1012.6PIK3CA, PIK3R2, PIK3R1, REL, RELA, RELB
16Transendothelial Migration of Leukocytes3612.6PIK3R2, PIK3R1, VCAM1, RAC1, PAK1, SDC1
17Fas Signaling3612.6RB1, RAF1, BID, BIRC2, BIRC3, PAK1
18Immune response_CD16 signaling in NK cells4112.5PIK3R2, PIK3R1, ZAP70, JUND, FOSB, INPP5D
19DR3 Signaling3612.4BID, BIRC2, BIRC3, CHUK, APAF1, FADD
20Development_EPO-induced Jak-STAT pathway4112.3MYC, BCL2, BCL2L1, CISH, XIAP, JAK2
21TREM1 Pathway3612.2PIK3R2, PIK3R1, BRAF, MYD88, RAF1, BID
22ICos-ICosL Pathway in T-Helper Cell3612.2PIK3R1, RAC1, CHUK, ZAP70, CD28, CD3D
23Focal adhesion2012.2PIK3CA, PIK3R2, PIK3R1, PIK3CG, VWF, VTN
24Immune response_IL-3 activation and signaling pathway4112.1RAF1, CISH, JUN, JUND, JAK2, FOS
25Bacterial infections in CF airways4111.9REL, RELA, RELB, MYD88, CHUK, MUC1
26Transcription_Role of VDR in regulation of genes involved in osteoporosis4111.9BGLAP, JUN, FOS, IL1A, IL1B, IL6
27eNOS Signaling3611.8PIK3R2, PIK3R1, KIT, KITLG, SEMA3A, BMP2
28Activation of PKC through GPCR3611.7PIK3R2, PIK3R1, KIT, KITLG, SEMA3A, BMP2
29Development_CNTF receptor signaling4111.7PIK3CA, PIK3R2, PIK3R1, CNTF, RAF1, MTOR
30mTOR Pathway3611.7PIK3R2, PIK3R1, KITLG, SEMA3A, BMP2, BMP4
31Development Thrombopoietin-regulated cell processes1011.6PIK3CA, PIK3R2, PIK3R1, BRAF, MYC, RAF1
32SUMO Pathway3611.6RANBP2, RAN, CHUK, IL1A, IL1B, IL1R1
33HMGB1 Pathway3611.6PIK3R2, PIK3R1, RAC1, JUN, FOS, IL1A
34Development HGF signaling pathway1011.6PIK3CA, PIK3R2, PIK3R1, RAF1, RAC1, SDC1
35Transcription Role of VDR in regulation of genes involved in osteoporosis1011.5BGLAP, JUN, FOS, IL1A, IL1B, IL6
36Development_Flt3 signaling4111.5PIK3CA, PIK3R2, PIK3R1, RAC1, PAK1, FYN
37Apoptosis and survival Role of CDK5 in neuronal death and survival1011.5BCL2, APAF1, CASP9, AKT3, CYCS
38Common Cytokine Receptor Gamma-Chain Family Signaling Pathways3711.5PIK3R1, PIK3CG, BRAF, RAF1, FOXO1, IRS1
39Development Neurotrophin family signaling1011.4PIK3CA, PIK3R2, PIK3R1, BRAF, RAF1, RAC1
40Cytoskeleton remodeling_FAK signaling4111.4PIK3CA, PIK3R2, PIK3R1, VEGFA, RAF1, RAC1
41Development_VEGF-family signaling4111.3PIK3CA, PIK3R2, PIK3R1, VTN, VEGFA, RAF1
42VEGF Signaling Pathway3411.3VEGFA, RAF1, KDR, ITGAV, ITGB3, FLT1
4314-3-3 Induced Intracellular Signaling3611.3PIK3R2, PIK3R1, KITLG, SEMA3A, BMP2, BMP4
44TGF-beta Signaling Pathways3711.3PIK3R2, PIK3R1, PIK3CG, NCOR2, REL, RELA
45Pertussis2011.3RELA, MYD88, JUN, CD14, ITGA5, ITGAM
46Epithelial cell signaling in Helicobacter pylori infection2011.3RELA, RAC1, PAK1, CHUK, JUN, MET
47Prolactin Signaling3611.2PIK3R2, BRAF, MYC, RAF1, CEBPB, FYN
48Allograft rejection2011.1CD28, CD40LG, CD80, CD40, GZMB, IL10
49Development_FGF-family signaling4111.0PIK3CA, PIK3R2, PIK3R1, RAF1, RAC1, FGF2
50Development Endothelin-1/EDNRA signaling1011.0PIK3CA, PIK3R2, PIK3R1, RAF1, RAC1, GSK3B

Compounds for genes affiliated with Multiple Myeloma

about this section
Sources:
32Novoseek , 9DrugBank, 18HMDB, 34PharmGKB, 42Tocris Bioscience
See all sources

Compounds related to multiple myeloma according to GeneDecks:

(show top 50)    (show all 430)
idCompoundScoreTop Affiliating Genes
1calcium32 9 18 9 35.6LRP1, RECK, REL, RELA, CNTF, KIT
2nitric oxide32 9 18 9 26.2NCAM1, REL, CNTF, KIT, KITLG, RB1
3atp32 22.0PIK3CA, PIK3R1, NCAM1, RECK, KIT, KIF11
4cholesterol32 9 18 9 21.4PIK3CA, PIK3R1, LRP1, RECK, KITLG, VWF
5glucose32 17.0CNTF, KIT, SETD2, BRAF, VHL, BNIP3
6paraffin32 16.8NCAM1, RELA, KIT, KITLG, VWF, PCNA
7estradiol32 9 18 9 19.5NCOR2, KITLG, PCNA, RB1, LIF, BIRC5
8ethanol32 34 9 18 9 19.4NCAM1, KITLG, BID, BDKRB2, BDNF, SCT
9hydrogen32 18 16.3BNIP3, RAC1, BDNF, SCT, CKS1B, CIITA
10sodium32 18 16.2PIK3CA, NCAM1, RECK, SFRP4, NAGLU, BRAF
11ascorbic acid32 18 16.1PIK3CG, CNTF, PCNA, RBP4, SETD2, NAT1
12iron32 18 15.2RECK, KITLG, RBP4, SETD2, NAGLU, VHL
13agarose32 14.1KIT, KITLG, VWF, MYC, LIF, BIRC2
14ifn-alpha32 14.1LIF, CISH, JAK1, CDK2, CDKN2A, IRF1
15magnesium32 9 18 9 16.9RBP4, NAGLU, RAG1, RAN, RAC1, PAK1
16ceramide32 13.7PIK3CA, PIK3R1, RB1, BNIP3, RAF1, BID
17phosphotyrosine32 13.6PIK3CA, PIK3R1, PIK3CG, RECK, KIT, RAF1
18daunorubicin32 9 9 15.3RELA, KITLG, MYC, RAF1, BIRC5, BCL2
19lactacystin32 13.2PIK3CG, MYC, RAF1, BIRC5, PARP1, BCL2
20methionine32 13.0RECK, CNTF, KIT, VWF, LIF, BDNF
21ganglioside32 12.8NCAM1, CNTF, CIITA, CD69, CD81, CD4
22docetaxel32 34 9 9 15.7KIT, SETD2, VEGFA, MYC, RAF1, BID
23noxa32 12.6BID, BIRC5, BCL2, BCL2L1, BCL2L11, BAK1
242-methoxyestradiol32 18 13.5PCNA, SETD2, BID, PAX5, BCL2, BCL2L1
25sulindac32 9 9 14.3PCNA, BIRC5, BCL2, BCL2L1, BAX, XIAP
26ifosfamide32 9 9 14.3NAGLU, B2M, CGB, MGMT, GSTM1, GSTP1
27vinblastine32 9 9 14.2RAF1, BIRC5, BDNF, KDR, BCL2, BCL2L1
28ibmx32 12.2VCAM1, BMP2, RAF1, BDNF, SCT, CIITA
2925-hydroxyvitamin d32 12.2SFRP4, BGLAP, PAX5, LEP, IL2RA, IGFBP4
30peptidoglycan32 12.2PIK3CA, MYD88, CIITA, CHUK, CD14, IL10
31anti-fungal32 12.1REL, CD79A, CDKN2A, CD40LG, FDFT1, IL15
32tpck32 12.1PIK3CG, PARP1, BCL2L1, BAK1, JUN, IL1B
33homocysteine32 18 13.0VWF, SELP, SERPINC1, NAGLU, NAT1, NAT2
34sodium dodecylsulfate32 11.9LRP1, VWF, VTN, MYC, BMP6, RAF1
35mycophenolate mofetil32 9 9 13.9SELP, CD79A, CD36, CD40LG, CD40, MMP1
36il 1032 11.9BMP6, LIF, CD40, IL10, IL10RA, IL12B
37cytochalasin d32 42 12.8PIK3CG, KITLG, VWF, VTN, VCAM1, RAF1
38alendronate32 9 9 13.8BMP2, BGLAP, PAX5, CD36, MMP1, MMP2
39ccl332 11.8MMP9, IL10, IL11, IL13, IL15, IL18
40ccl432 11.6MET, IL12B, IL13, IL15, IL16, IL17A
41c2ceramide32 11.6PIK3CG, PARP1, BCL2L1, CHUK, BAX, JUN
42vitamin b1232 11.6VWF, PCNA, MTRR, MTHFR, MTR, B2M
43norepinephrine32 9 18 9 14.5CNTF, KITLG, VWF, SELP, VCAM1, BMP6
44glucosamine32 9 18 9 14.4SERPINC1, CD36, CD40, IRS1, IRS2, FGF2
45caffeine32 34 9 18 9 15.4PIK3R1, PCNA, NAT1, NAT2, BMP6, RAG2
46methimazole32 9 9 13.4VWF, PCNA, BGLAP, CD69, IL13, IL2RA
47carbon32 11.2VWF, VTN, PCNA, MTHFR, MT-CYB, MTR
48polymyxin b32 11.2VCAM1, P2RX7, CD14, ITGB2, IL10, IL1A
49rotenone32 11.1PIK3CG, PARP1, BCL2, BCL2L1, IL1A, IL1RAPL2
50rosiglitazone32 9 18 9 14.1PIK3CA, PIK3CG, LRP1, RBP4, VCAM1, LEP

GO Terms for genes affiliated with Multiple Myeloma

about this section
Sources:
12Gene Ontology
See all sources

Cellular components related to multiple myeloma according to GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1plasma membraneGO:00588627.1PIK3R1, PIK3CG, NCAM1, RECK, KIT, KITLG
2cytoplasmGO:00573726.5PIAS3, PIK3CG, LRP1, PDCD5, RELA, KIT
3nucleusGO:00563426.5PIAS3, LRP1, NCOR2, PDCD5, RELA, RELB
4cytosolGO:00582923.9PIK3CA, PIK3R2, PIK3R1, PIK3CG, REL, RELA
5extracellular spaceGO:00561519.5CNTF, KIT, KITLG, VTN, SFRP1, SFRP2
6extracellular regionGO:00557618.8NCAM1, KITLG, VWF, VTN, SERPINC1, SEMA3A
7integral to plasma membraneGO:00588718.7LRP1, NCR1, KIR3DS1, KIR2DS4, SELP, BST2
8nucleoplasmGO:00565415.2NCOR2, REL, RELA, PCNA, RB1, VHL
9external side of plasma membraneGO:00989715.0NCAM1, KIT, VWF, SELP, VCAM1, KDR
10cell surfaceGO:00998613.4NCAM1, SFRP1, SFRP4, BST2, VEGFA, VCAM1

Biological processes related to multiple myeloma according to GeneDecks:

(show top 50)    (show all 74)
idNameGO IDScoreTop Affiliating Genes
1signal transductionGO:00716520.9NCR1, CNTF, KIT, KITLG, SFRP5, BST2
2apoptotic processGO:00691519.7PDCD5, SFRP5, SEMA3A, BNIP3, RAF1, RAC1
3immune responseGO:00695517.7KIR3DS1, VTN, BMP6, RAG1, LIF, CIITA
4anti-apoptosisGO:00691615.3PIK3CA, RELA, BRAF, VHL, BNIP3, MYD88
5innate immune responseGO:04508715.2PIK3CG, RELA, BST2, MYD88, BCL10, BCL2
6cytokine-mediated signaling pathwayGO:01922115.1NCAM1, RELA, KIT, VCAM1, MYD88, RANBP2
7negative regulation of transcription from RNA polymerase II promoterGO:00012214.8NCOR2, VHL, MYC, BMI1, BMP2, BMP4
8positive regulation of transcription from RNA polymerase II promoterGO:04594414.8RELA, SFRP2, RB1, VEGFA, MYC, MYD88
9cell-cell signalingGO:00726714.7SFRP2, BST2, BMP2, CGB, CD70, CD80
10inflammatory responseGO:00695414.7PIK3CG, RELA, KIT, SELP, MYD88, BMP2
11induction of apoptosisGO:00691714.2PDCD5, BNIP3, BIK, BCL10, BCL2L11, BAX
12response to drugGO:04249313.9SFRP1, SFRP2, MYC, BGLAP, BDKRB2, BDNF
13negative regulation of transcription, DNA-dependentGO:04589213.9RELA, SFRP1, SFRP2, RB1, BMP2, BMP4
14negative regulation of cell proliferationGO:00828513.7SFRP1, SFRP2, SFRP4, SFRP5, BTG1, VHL
15cell surface receptor signaling pathwayGO:00716613.7MYD88, BIRC2, BIRC3, BDKRB2, LAG3, P2RX7
16virus-host interactionGO:01904813.6PIK3R1, RELA, RB1, VCAM1, BNIP3, RAN
17regulation of immune responseGO:05077613.5VCAM1, BCL6, B2M, CD3D, CD81, CD3G
18positive regulation of transcription, DNA-dependentGO:04589313.4REL, RELA, SFRP1, RB1, VHL, MYC
19induction of apoptosis by extracellular signalsGO:00862413.2RAC1, BCL2L11, BAK1, BAX, CFLAR, CD3E
20activation of cysteine-type endopeptidase activity involved in apoptotic processGO:00691913.1MYC, BCL2L11, BAX, JAK2, CDKN1B, CDKN2A
21activation of pro-apoptotic gene productsGO:00863312.8MYC, BID, BCL2, BCL2L11, BAK1, BAX
22nerve growth factor receptor signaling pathwayGO:04801112.8PIK3CA, PIK3R2, PIK3R1, RELA, BRAF, MYD88
23response to lipopolysaccharideGO:03249612.6SELP, BDKRB1, P2RX7, CEBPB, JUN, JAK2
24T cell costimulationGO:03129512.6PIK3CA, PIK3R2, PIK3R1, RAC1, PAK1, MTOR
25induction of apoptosis by intracellular signalsGO:00862912.5BNIP3, MYC, BID, BCL2, BCL2L1, BCL2L11
26leukocyte migrationGO:05090012.5PIK3CA, PIK3R2, PIK3R1, SELP, FYN, CD58
27insulin receptor signaling pathwayGO:00828612.4PIK3CA, PIK3R2, PIK3R1, RAF1, MTOR, CDK1
28positive regulation of peptidyl-tyrosine phosphorylationGO:05073112.4KITLG, VTN, VEGFA, LIF, MTOR, JAK2
29positive regulation of gene expressionGO:01062812.3PIAS3, RELB, KIT, SFRP4, BRAF, VEGFA
30toll-like receptor signaling pathwayGO:00222412.2RELA, MYD88, BCL10, CHUK, JUN, CDK1
31positive regulation of apoptotic processGO:04306512.1SFRP1, SFRP2, SFRP4, BMP2, BMP4, BID
32response to organic cyclic compoundGO:01407011.9SFRP1, SELP, BMP4, BAK1, P2RX7, JUN
33toll-like receptor 4 signaling pathwayGO:03414211.9RELA, MYD88, CHUK, JUN, CD14, CDK1
34toll-like receptor 3 signaling pathwayGO:03413811.9RELA, CHUK, JUN, CD14, CDK1, FOS
35TRIF-dependent toll-like receptor signaling pathwayGO:03566611.9RELA, CHUK, JUN, CD14, CDK1, FOS
36activation of MAPK activityGO:00018711.8KIT, S1PR2, P2RX7, CD81, CD74, CDK1
37Ras protein signal transductionGO:00726511.7RB1, RAF1, RALA, RALB, CDKN1A, CDK2
38angiogenesisGO:00152511.7PIK3CA, PIK3CG, SETD2, VEGFA, KDR, JUN
39toll-like receptor 1 signaling pathwayGO:03413011.7RELA, MYD88, CHUK, JUN, CDK1, FOS
40toll-like receptor 2 signaling pathwayGO:03413411.7RELA, MYD88, CHUK, JUN, CDK1, FOS
41blood coagulationGO:00759611.7PIK3CA, PIK3R2, PIK3R1, PIK3CG, KIF11, VWF
42phosphatidylinositol-mediated signalingGO:04801511.5PIK3CA, PIK3R2, PIK3R1, PCNA, CHUK, MTOR
43fibroblast growth factor receptor signaling pathwayGO:00854311.4PIK3CA, PIK3R1, BRAF, RAF1, CHUK, MTOR
44positive regulation of peptidyl-serine phosphorylationGO:03313811.4PIK3CA, SFRP2, BRAF, VEGFA, RAF1, LIF
45response to ethanolGO:04547111.4RBP4, BGLAP, BCL2, BAK1, FYN, CD27
46T cell receptor signaling pathwayGO:05085211.4PIK3CA, PIK3R2, PIK3R1, RELA, PAK1, BCL10
47response to hypoxiaGO:00166611.3VEGFA, VCAM1, BNIP3, BMP2, RAF1, PAK1
48positive regulation of smooth muscle cell proliferationGO:04866110.7MYD88, BMP4, JUN, FLT1, IL13, IL6
49epidermal growth factor receptor signaling pathwayGO:00717310.6PIK3CA, PIK3R1, RAF1, CHUK, MTOR, CDKN1B
50platelet activationGO:03016810.1PIK3CA, PIK3R2, PIK3R1, PIK3CG, VWF, SELP

Molecular functions related to multiple myeloma according to GeneDecks:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1protein bindingGO:00551538.3HDAC1, ADA, EEF1G, WNT3A, SIN3B, SIK2
2cytokine activityGO:00512516.3CSF3, CSF2, CSF1, CXCL9, OSM, THPO
3receptor activityGO:00487214.8NOTCH2, NOTCH1, PLXNA1, PLAUR, DARC, TNFRSF9
4protein kinase bindingGO:01990113.5CDKN2B, CDC37, CDKN2C, JAK2, AURKA, BCL2L1
5growth factor activityGO:00808313.2CSF1, IGF1, IGF2, MDK, IL9, IL7
6protein heterodimerization activityGO:04698213.2TLR1, MAF, MCL1, IL12B, IL12A, MET
7identical protein bindingGO:04280212.9THBS1, CASP8, HSP90AA1, IGF1R, FAS, FADD
8receptor bindingGO:00510212.8TNFSF8, TNFSF4, TNFSF18, TNFSF14, TNFSF13B, TNFSF13
9tumor necrosis factor receptor bindingGO:00516412.8STAT1, CASP8, FADD, FASLG, CD40LG, CD70
10transmembrane signaling receptor activityGO:00488812.7TNFRSF8, TNFRSF11A, TNFRSF10D, TNFRSF10C, ERBB2, DARC
11transcription factor bindingGO:00813412.2HIF1A, NFKBIA, PPP1R13L, CTNNB1, SP1, TNFRSF10A
12protein homodimerization activityGO:04280311.8TERT, PTGS2, SP1, NTRK2, NR3C1, TERF2
13enzyme bindingGO:01989910.9LYN, SLPI, CSF3, PRKCA, STAT1, TGFB1

Sources for Multiple Myeloma

about this section
2CDC
11FMA
18HMDB
19ICD9CM
20KEGG
24MeSH
25MGI
27NCIt
28NDF-RT
31NINDS
32Novoseek
33OMIM
35PubMed
36QIAGEN
43UMLS
Browse MalaCards: 1-9 | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z